Antibody-drug conjugate · Cytotoxic, directed at glycoprotein NMB (GPNMB) (GPNMB) · developed by Celldex Therapeutics
Glembatumumab vedotin is an antibody-drug conjugate in which the fully human antibody CR011 binds GPNMB, a transmembrane protein overexpressed on various cancer cells. After internalization, the linked cytotoxic agent monomethyl auristatin E (MMAE) is released and inhibits tubulin polymerization. It is studied in GPNMB-overexpressing triple negative breast cancer, melanoma and squamous cell carcinoma of the lung.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02713828 | Phase 1/2 | Squamous Cell Carcinoma of the Lung | Terminated | CLDX |
| NCT02302339 | Phase 2 | Melanoma | Terminated | CLDX |
| NCT01997333 | Phase 2 | Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | Completed | CLDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
MelanomaSquamous Cell Carcinoma of the Lung
Updated Oct 11, 2026. Something wrong or missing? Report it on the CLDX page.
See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLDX catalysts and pipeline →